Next Article in Journal
Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations
Previous Article in Journal
Use of Chemotherapy and Radiofrequency Ablation to Treat Colorectal Cancer Metastases: A Retrospective Review of the Ottawa Hospital Cancer Centre over 7 Years
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Open AccessArticle

Factors Associated with Publication of Randomized Phase iii Cancer Trials in Journals with a High Impact Factor

by 1,*, 2, 3 and 4
1
Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada
2
Department of Oncology, Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada
3
Department of Medical Oncology, London Regional Cancer Program, London, ON, Canada
4
Department of Medical Oncology and Hematology, Princess Margaret Hospital, and Faculty of Medicine, University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(4), 564-572; https://doi.org/10.3747/co.21.1937
Received: 7 May 2014 / Revised: 4 June 2014 / Accepted: 4 July 2014 / Published: 1 August 2014
(1) Background: Impact factor (if) is often used as a measure of journal quality. The purpose of the present study was to determine whether trials with positive outcomes are more likely to be published in journals with higher ifs. (2) Methods: We reviewed 476 randomized phase iii cancer trials published in 13 journals between 1995 and 2005. Multivariate logistic regression models were used to investigate predictors of publication in journals with high ifs (compared with low and medium ifs). (3) Results: A positive outcome had the strongest association with publication in high-if journals [odds ratio (or): 4.13; 95% confidence interval (ci): 2.67 to 6.37; p < 0.001]. Other associated factors were a larger sample size (or: 1.06; 95% ci: 1.02 to 1.10; p = 0.001), intention-to-treat analysis (or: 2.53; 95% ci: 1.56 to 4.10; p < 0.001), North American authors (or for European authors: 0.36; 95% ci: 0.23 to 0.58; or for international authors: 0.41; 95% ci: 0.20 to 0.82; p < 0.001), adjuvant therapy trial (or: 2.58; 95% ci: 1.61 to 4.15; p < 0.001), shorter time to publication (or: 0.84; 95% ci: 0.77 to 0.92; p < 0.001), uncommon tumour type (or: 1.39; 95% ci: 0.90 to 2.13; p = 0.012), and hematologic malignancy (or: 3.15; 95% ci: 1.41 to 7.03; p = 0.012). (4) Conclusions: Cancer trials with positive outcomes are more likely to be published in journals with high ifs. Readers of medical literature should be aware of this “impact factor bias,” and investigators should be encouraged to submit reports of trials of high methodologic quality to journals with high ifs regardless of study outcomes.
Keywords: impact factor; cancer trials; publication; predictive factors impact factor; cancer trials; publication; predictive factors
MDPI and ACS Style

Tang, P.A.; Pond, G.R.; Welch, S.; Chen, E.X. Factors Associated with Publication of Randomized Phase iii Cancer Trials in Journals with a High Impact Factor. Curr. Oncol. 2014, 21, 564-572. https://doi.org/10.3747/co.21.1937

AMA Style

Tang PA, Pond GR, Welch S, Chen EX. Factors Associated with Publication of Randomized Phase iii Cancer Trials in Journals with a High Impact Factor. Current Oncology. 2014; 21(4):564-572. https://doi.org/10.3747/co.21.1937

Chicago/Turabian Style

Tang, P.A.; Pond, G.R.; Welch, S.; Chen, E.X. 2014. "Factors Associated with Publication of Randomized Phase iii Cancer Trials in Journals with a High Impact Factor" Curr. Oncol. 21, no. 4: 564-572. https://doi.org/10.3747/co.21.1937

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop